{"id":252,"date":"2022-01-28T10:10:59","date_gmt":"2022-01-28T10:10:59","guid":{"rendered":"https:\/\/amm-journal.org\/?p=252"},"modified":"2022-01-28T10:10:59","modified_gmt":"2022-01-28T10:10:59","slug":"protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives","status":"publish","type":"post","link":"https:\/\/amm-journal.org\/index.php\/2022\/01\/28\/protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives\/","title":{"rendered":"PROTAC Technology for the Treatment of Alzheimer\u2019s Disease: Advances and Perspectives"},"content":{"rendered":"<p>Announcing a new review article publication for<em> Acta Materia Medica<\/em> journal. Although PROTAC technology is preferable to oligonucleotides and antibodies for the treatment of neurodegenerative diseases, many limitations, such as their pharmacokinetic properties, tissue distribution, and cell permeability, must be addressed. The authors of this article review recent advances in PROTAC technology, as well as PROTACs\u2019 limitations, for the pharmaceutical targeting of aberrant proteins involved in AD and the therapeutic potential of dysregulated signaling, such as the PI3K\/AKT\/mTOR axis, for the management of AD.<\/p>\n<p>Neurodegenerative diseases are characterized by the progression of neuronal degeneration, resulting in dysfunction of cognition and mobility. Many neurodegenerative diseases are due to proteinopathies arising from unusual protein accumulation and aggregation. The aggregation of misfolded proteins, such as \u03b2-amyloid, \u03b1-synuclein, tau, and polyglutamates, is a hallmark of Alzheimer\u2019s disease (AD). These aggregated proteins are undruggable targets and usually do not respond to conventional small-molecule agents. Therefore, developing novel technologies and strategies for decreasing the levels of protein aggregates is critical for the treatment of AD. Recently, the emerging proteolysis targeting chimera (PROTAC) technology has been considered for artificial, selective degradation of aberrant target proteins. These engineered bifunctional molecules engage target proteins, which are then degraded either by the cellular degradation machinery <em>via <\/em>the ubiquitin-proteasome system or through the autophagylysosome degradation pathway.<\/p>\n<p><strong>Article Reference:<\/strong> Hiroyuki Inuzuka, Jing Liu and Wenyi Wei et al. PROTAC technology for the treatment of Alzheimer\u2019s disease: advances and perspectives.\u00a0<em>Acta Materia Medica.\u00a0<\/em>Vol. 1(1). DOI: 10.15212\/AMM-2021-0001<\/p>\n<p><strong>Keywords:<\/strong> PROTAC, ubiquitin-proteasome system, protein degradation, autophagy, Alzheimer\u2019s disease<\/p>\n<p>https:\/\/www.scienceopen.com\/hosted-document?doi=10.15212\/AMM-2021-0001<\/p>\n<p><em>Acta Materia Medica<\/em> welcomes the submission of research articles, review articles, databases, mini reviews, commentaries, editorials, short communications, case report articles and study protocols.<\/p>\n<p><strong>Submission Process<\/strong><\/p>\n<p>Submissions <em>to Acta Materia Medica<\/em> are made using ScholarOne, the online submission and peer review system. Registration and access are available at <a href=\"https:\/\/mc04.manuscriptcentral.com\/ammed\">https:\/\/mc04.manuscriptcentral.com\/ammed<\/a><\/p>\n<p>Queries about the journal can be sent to editorialoffice@amm-journal.org.<\/p>\n<p>Please visit <a href=\"https:\/\/amm-journal.org\/\">https:\/\/amm-journal.org\/<\/a> to learn more about the journal.<\/p>\n<p><strong>Editorial Board:<\/strong> <a href=\"https:\/\/amm-journal.org\/index.php\/editorial-board\/\">https:\/\/amm-journal.org\/index.php\/editorial-board\/<\/a><\/p>\n<p>There are no author submission or article processing fees.<\/p>\n<p>Follow <strong><em>Acta Materia Medica <\/em><\/strong>on Twitter <a href=\"https:\/\/twitter.com\/AMM_journal\">https:\/\/twitter.com\/AMM_journal<\/a>\u00a0 ; <a href=\"https:\/\/www.facebook.com\/Zoonoses-Journal-100462755574114\">Facebook<\/a> (<a href=\"https:\/\/www.facebook.com\/AMMjournal\">https:\/\/www.facebook.com\/AMMjournal<\/a>)<\/p>\n<p><strong>eISSN <\/strong>2737-7946<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announcing a new review article publication for Acta Materia Medica journal. Although PROTAC technology is preferable to oligonucleotides and antibodies for the treatment of neurodegenerative diseases, many limitations, such as their pharmacokinetic properties, tissue distribution, and cell permeability, must be addressed. The authors of this article review recent advances in PROTAC technology, as well as [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[17,16,13,15,14],"class_list":["post-252","post","type-post","status-publish","format-standard","hentry","category-news-and-events","tag-alzheimers-disease","tag-autophagy","tag-protac","tag-protein-degradation","tag-ubiquitin-proteasome-system"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PROTAC Technology for the Treatment of Alzheimer\u2019s Disease: Advances and Perspectives - AMM Journal<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/amm-journal.org\/index.php\/2022\/01\/28\/protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PROTAC Technology for the Treatment of Alzheimer\u2019s Disease: Advances and Perspectives - AMM Journal\" \/>\n<meta property=\"og:description\" content=\"Announcing a new review article publication for Acta Materia Medica journal. Although PROTAC technology is preferable to oligonucleotides and antibodies for the treatment of neurodegenerative diseases, many limitations, such as their pharmacokinetic properties, tissue distribution, and cell permeability, must be addressed. The authors of this article review recent advances in PROTAC technology, as well as [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/amm-journal.org\/index.php\/2022\/01\/28\/protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives\/\" \/>\n<meta property=\"og:site_name\" content=\"AMM Journal\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-28T10:10:59+00:00\" \/>\n<meta name=\"author\" content=\"Compuscript\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Compuscript\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/amm-journal.org\\\/index.php\\\/2022\\\/01\\\/28\\\/protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/amm-journal.org\\\/index.php\\\/2022\\\/01\\\/28\\\/protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives\\\/\"},\"author\":{\"name\":\"Compuscript\",\"@id\":\"https:\\\/\\\/amm-journal.org\\\/#\\\/schema\\\/person\\\/0935dba5c919585e39f756ce09930a67\"},\"headline\":\"PROTAC Technology for the Treatment of Alzheimer\u2019s Disease: Advances and Perspectives\",\"datePublished\":\"2022-01-28T10:10:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/amm-journal.org\\\/index.php\\\/2022\\\/01\\\/28\\\/protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives\\\/\"},\"wordCount\":391,\"commentCount\":0,\"keywords\":[\"Alzheimer\u2019s disease\",\"autophagy\",\"PROTAC\",\"protein degradation\",\"ubiquitin-proteasome system\"],\"articleSection\":[\"News and Events\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/amm-journal.org\\\/index.php\\\/2022\\\/01\\\/28\\\/protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/amm-journal.org\\\/index.php\\\/2022\\\/01\\\/28\\\/protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives\\\/\",\"url\":\"https:\\\/\\\/amm-journal.org\\\/index.php\\\/2022\\\/01\\\/28\\\/protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives\\\/\",\"name\":\"PROTAC Technology for the Treatment of Alzheimer\u2019s Disease: Advances and Perspectives - AMM Journal\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/amm-journal.org\\\/#website\"},\"datePublished\":\"2022-01-28T10:10:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/amm-journal.org\\\/#\\\/schema\\\/person\\\/0935dba5c919585e39f756ce09930a67\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/amm-journal.org\\\/index.php\\\/2022\\\/01\\\/28\\\/protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/amm-journal.org\\\/index.php\\\/2022\\\/01\\\/28\\\/protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/amm-journal.org\\\/index.php\\\/2022\\\/01\\\/28\\\/protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/amm-journal.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PROTAC Technology for the Treatment of Alzheimer\u2019s Disease: Advances and Perspectives\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/amm-journal.org\\\/#website\",\"url\":\"https:\\\/\\\/amm-journal.org\\\/\",\"name\":\"AMM Journal\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/amm-journal.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/amm-journal.org\\\/#\\\/schema\\\/person\\\/0935dba5c919585e39f756ce09930a67\",\"name\":\"Compuscript\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb3d42af3c1b48f4d76adf5524c6c3447a369d2a7bcb666ef995240441912a6b?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb3d42af3c1b48f4d76adf5524c6c3447a369d2a7bcb666ef995240441912a6b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fb3d42af3c1b48f4d76adf5524c6c3447a369d2a7bcb666ef995240441912a6b?s=96&d=mm&r=g\",\"caption\":\"Compuscript\"},\"sameAs\":[\"https:\\\/\\\/amm-journal.org\"],\"url\":\"https:\\\/\\\/amm-journal.org\\\/index.php\\\/author\\\/ammjadmin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PROTAC Technology for the Treatment of Alzheimer\u2019s Disease: Advances and Perspectives - AMM Journal","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/amm-journal.org\/index.php\/2022\/01\/28\/protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives\/","og_locale":"en_GB","og_type":"article","og_title":"PROTAC Technology for the Treatment of Alzheimer\u2019s Disease: Advances and Perspectives - AMM Journal","og_description":"Announcing a new review article publication for Acta Materia Medica journal. Although PROTAC technology is preferable to oligonucleotides and antibodies for the treatment of neurodegenerative diseases, many limitations, such as their pharmacokinetic properties, tissue distribution, and cell permeability, must be addressed. The authors of this article review recent advances in PROTAC technology, as well as [&hellip;]","og_url":"https:\/\/amm-journal.org\/index.php\/2022\/01\/28\/protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives\/","og_site_name":"AMM Journal","article_published_time":"2022-01-28T10:10:59+00:00","author":"Compuscript","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Compuscript","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/amm-journal.org\/index.php\/2022\/01\/28\/protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives\/#article","isPartOf":{"@id":"https:\/\/amm-journal.org\/index.php\/2022\/01\/28\/protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives\/"},"author":{"name":"Compuscript","@id":"https:\/\/amm-journal.org\/#\/schema\/person\/0935dba5c919585e39f756ce09930a67"},"headline":"PROTAC Technology for the Treatment of Alzheimer\u2019s Disease: Advances and Perspectives","datePublished":"2022-01-28T10:10:59+00:00","mainEntityOfPage":{"@id":"https:\/\/amm-journal.org\/index.php\/2022\/01\/28\/protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives\/"},"wordCount":391,"commentCount":0,"keywords":["Alzheimer\u2019s disease","autophagy","PROTAC","protein degradation","ubiquitin-proteasome system"],"articleSection":["News and Events"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/amm-journal.org\/index.php\/2022\/01\/28\/protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/amm-journal.org\/index.php\/2022\/01\/28\/protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives\/","url":"https:\/\/amm-journal.org\/index.php\/2022\/01\/28\/protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives\/","name":"PROTAC Technology for the Treatment of Alzheimer\u2019s Disease: Advances and Perspectives - AMM Journal","isPartOf":{"@id":"https:\/\/amm-journal.org\/#website"},"datePublished":"2022-01-28T10:10:59+00:00","author":{"@id":"https:\/\/amm-journal.org\/#\/schema\/person\/0935dba5c919585e39f756ce09930a67"},"breadcrumb":{"@id":"https:\/\/amm-journal.org\/index.php\/2022\/01\/28\/protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/amm-journal.org\/index.php\/2022\/01\/28\/protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/amm-journal.org\/index.php\/2022\/01\/28\/protac-technology-for-the-treatment-of-alzheimers-disease-advances-and-perspectives\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/amm-journal.org\/"},{"@type":"ListItem","position":2,"name":"PROTAC Technology for the Treatment of Alzheimer\u2019s Disease: Advances and Perspectives"}]},{"@type":"WebSite","@id":"https:\/\/amm-journal.org\/#website","url":"https:\/\/amm-journal.org\/","name":"AMM Journal","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/amm-journal.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/amm-journal.org\/#\/schema\/person\/0935dba5c919585e39f756ce09930a67","name":"Compuscript","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/fb3d42af3c1b48f4d76adf5524c6c3447a369d2a7bcb666ef995240441912a6b?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/fb3d42af3c1b48f4d76adf5524c6c3447a369d2a7bcb666ef995240441912a6b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fb3d42af3c1b48f4d76adf5524c6c3447a369d2a7bcb666ef995240441912a6b?s=96&d=mm&r=g","caption":"Compuscript"},"sameAs":["https:\/\/amm-journal.org"],"url":"https:\/\/amm-journal.org\/index.php\/author\/ammjadmin\/"}]}},"_links":{"self":[{"href":"https:\/\/amm-journal.org\/index.php\/wp-json\/wp\/v2\/posts\/252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/amm-journal.org\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/amm-journal.org\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/amm-journal.org\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/amm-journal.org\/index.php\/wp-json\/wp\/v2\/comments?post=252"}],"version-history":[{"count":1,"href":"https:\/\/amm-journal.org\/index.php\/wp-json\/wp\/v2\/posts\/252\/revisions"}],"predecessor-version":[{"id":253,"href":"https:\/\/amm-journal.org\/index.php\/wp-json\/wp\/v2\/posts\/252\/revisions\/253"}],"wp:attachment":[{"href":"https:\/\/amm-journal.org\/index.php\/wp-json\/wp\/v2\/media?parent=252"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/amm-journal.org\/index.php\/wp-json\/wp\/v2\/categories?post=252"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/amm-journal.org\/index.php\/wp-json\/wp\/v2\/tags?post=252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}